The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2020 | Academic vs. commercial CAR T-cell products
Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, compares academic and commercial CAR T-cell products. Academic products give more flexibility to treat patients and have a lower cost, but from the regulatory perspective, commercial products may be preferable. Prof. Nagler believes there is room for both academic and commercial CAR T-cell products. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
